The competition between Sarepta, Pfizer and Solid Biosciences to market gene therapy for the genetic degeneration disorder Duchenne muscular dystrophy (DMD) has intensified after safety problems emerged from Pfizer’s clinical tests. Shares in Sarepta, which has already launched a treatment called Exondys 51 for certain DMD variations, rose 15% after the concerns emerged following an early stage study on Pfizer’s product. The U.S. drugmaker said it also may test an intermediate dose. Sarepta, meanwhile, had reported promising results from its own study into the disorder, which affects one male in 3,500-5,000. In addition to the two companies, other companies are also testing drugs that could be used as treatments for DMD.
The competition between Sarepta, Pfizer and Solid Biosciences to market gene therapy for the genetic degeneration disorder Duchenne muscular dystrophy (DMD) has intensified after safety problems emerged from Pfizer’s clinical tests. Shares in Sarepta, which has already launched a treatment called Exondys 51 for certain DMD variations, rose 15% after the concerns emerged following an early stage study on Pfizer’s product. Sarepta, meanwhile, had reported promising results from its own study into the disorder, which affects one male in 3,500-5,000. In addition to the two companies, other companies are also testing drugs that could be used as treatments for DMD.